The TreatER project brings together public and private sector partners from five European countries for the development of a better treatment for Parkinson’s disease. The main focus of the TreatER project is to conduct a first-in-human clinical study with intracerebrally administered CDNF protein in people with Parkinson’s disease (PD) using a neurosurgically implanted Drug Delivery System (DDS).
The TreatER project has two independent goals, each of which can individually have a significant impact in addressing unmet clinical needs in chronic diseases, and in advancing innovative European technologies:
The clinical study builds on extensive preclinical research and related data on CDNF, including completed acute and chronic toxicology studies in non-human primates supporting an excellent safety profile. Further, the clinical study builds on existing clinical experience in DDS and related neurosurgery.
The TreatER project will be executed during 2017-20. The project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 732386. The project was funded under H2020-EU.3.1.3. – Treating and managing disease (SC1-PM-09-2016 – New therapies for chronic diseases). The official title of the Horizon2020 funded project is “Clinical study in Parkinson’s disease with two unique goals: 1) Proof-of-concept of CDNF protein for disease modification; 2) Validation of clinically tested device for intracerebral drug delivery” (link to Horizon 2020 project database).